Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,584
  • Shares Outstanding, K 220,416
  • Annual Sales, $ 8,950 K
  • Annual Income, $ -21,490 K
  • EBIT $ -23 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.16
  • Price/Sales 13.52
  • Price/Cash Flow N/A
  • Price/Book 1.63
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.12
  • Most Recent Earnings $-0.02 on 11/14/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.080 on 12/15/03
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 284.76% ( -99.21%)
  • Historical Volatility 137.78%
  • IV Percentile 40%
  • IV Rank 19.75%
  • IV High 1,295.13% on 05/22/24
  • IV Low 36.07% on 10/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 137
  • Volume Avg (30-Day) 130
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 5,228
  • Open Int (30-Day) 5,227

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.04
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4810 +11.85%
on 12/17/24
0.6200 -13.23%
on 12/11/24
+0.0341 (+6.77%)
since 11/22/24
3-Month
0.4810 +11.85%
on 12/17/24
0.9700 -44.54%
on 11/12/24
-0.3560 (-39.82%)
since 09/24/24
52-Week
0.4810 +11.85%
on 12/17/24
1.6100 -66.58%
on 03/28/24
-0.5520 (-50.64%)
since 12/22/23

Most Recent Stories

More News
Insider Purchase: President and CEO of $LCTX (LCTX) Buys 40,000 Shares

Brian M Culley, the President and CEO of $LCTX ($LCTX), bought 40,000 shares of the company on 11-21-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

LCTX : 0.5380 (-1.91%)
5 Stocks Retail Investors Are Most Bearish On At Mid-Day

Disappointing retail earnings and concerns about bloated valuations are weighing down on retail sentiment toward some stocks.

WSM : 187.73 (+0.65%)
MSTR : 358.18 (+7.81%)
XP : 12.12 (-0.16%)
LCTX : 0.5380 (-1.91%)
SPY : 601.30 (+1.11%)
ELF : 131.91 (+2.30%)
XBI : 91.98 (+0.10%)
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 0.5380 (-1.91%)
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging...

LCTX : 0.5380 (-1.91%)
Lineage to Present at 2023 AAPS National Biotechnology Conference

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley,...

LCTX : 0.5380 (-1.91%)
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation...

LCTX : 0.5380 (-1.91%)
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a...

LCTX : 0.5380 (-1.91%)
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating...

LCTX : 0.5380 (-1.91%)
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging...

LCTX : 0.5380 (-1.91%)
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 0.5380 (-1.91%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 0.5683
2nd Resistance Point 0.5591
1st Resistance Point 0.5486
Last Price 0.5380
1st Support Level 0.5289
2nd Support Level 0.5197
3rd Support Level 0.5092

See More

52-Week High 1.6100
Fibonacci 61.8% 1.1787
Fibonacci 50% 1.0455
Fibonacci 38.2% 0.9123
Last Price 0.5380
52-Week Low 0.4810

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar